- Home
- VRCA vs CVRX Comparison
VRCA vs CVRX Comparison
Compare VRCA & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- CVRX
- Stock Information
- Founded
- VRCA 2013
- CVRX 2000
- Country
- VRCA United States
- CVRX United States
- Employees
- VRCA N/A
- CVRX N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- VRCA Health Care
- CVRX Health Care
- Exchange
- VRCA Nasdaq
- CVRX Nasdaq
- Market Cap
- VRCA 363.1M
- CVRX 311.3M
- IPO Year
- VRCA 2018
- CVRX 2021
- Fundamental
- Price
- VRCA $0.69
- CVRX $12.11
- Analyst Decision
- VRCA Hold
- CVRX Buy
- Analyst Count
- VRCA 5
- CVRX 7
- Target Price
- VRCA $6.00
- CVRX $16.67
- AVG Volume (30 Days)
- VRCA 749.9K
- CVRX 187.2K
- Earning Date
- VRCA 11-04-2024
- CVRX 01-23-2025
- Dividend Yield
- VRCA N/A
- CVRX N/A
- EPS Growth
- VRCA N/A
- CVRX N/A
- EPS
- VRCA N/A
- CVRX N/A
- Revenue
- VRCA $9,210,000.00
- CVRX $47,255,000.00
- Revenue This Year
- VRCA $54.16
- CVRX $31.78
- Revenue Next Year
- VRCA $99.78
- CVRX $26.42
- P/E Ratio
- VRCA N/A
- CVRX N/A
- Revenue Growth
- VRCA 187.45
- CVRX 34.38
- 52 Week Low
- VRCA $0.61
- CVRX $6.40
- 52 Week High
- VRCA $11.41
- CVRX $33.14
- Technical
- Relative Strength Index (RSI)
- VRCA 33.00
- CVRX 38.54
- Support Level
- VRCA $0.61
- CVRX $12.57
- Resistance Level
- VRCA $1.32
- CVRX $13.68
- Average True Range (ATR)
- VRCA 0.11
- CVRX 0.85
- MACD
- VRCA -0.02
- CVRX -0.35
- Stochastic Oscillator
- VRCA 12.08
- CVRX 17.11
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.